February 2021

"Viral Outbreaks", new book by IntechOpen, includes a chapter on trained immunity-based vaccines (TIbVs) with the participation of INMUNOTEK. These are broad-spectrum vaccines that could play an important role in temporarily protecting vulnerable people from dangerous viruses in the absence of effective specific vaccines.
More info

January 2021

A scoring proposal that combines symptoms and medication for the monitoring of allergic asthma in immunotherapy treatments is published in the International Archives of Allergy and Immunology. This proposal, developed by INMUNOTEK, facilitates the evaluation of the efficacy of immunotherapy in clinical trials.
More info

January 2021

According to research published in Frontiers in Immunology, the response to Candida albicans is enhanced and improved in combination with MV140 (Uromune). Recurrent vulvovaginal candidiasis is a common infection. Prevention measures and treatments are still limited. It is often associated with urinary tract infections as a consequence of antibiotic treatment. Uromune is a bacterial vaccine used to prevent recurrent urinary infections. In this experimental study it is demonstrated how the combination of MV140 with Candida albicans enhances the response against this fungus, favoring the specific and non-specific cellular response, as well as the antibody response.
More info

November 2020

Frontiers in Immunology publishes a study on the effect of MV130 (Bactek) on mesenchymal stem cells. These cells are acquiring a leading role not only for their differentiation capacity but also for their emerging immunomodulatory activity. Mesenchymal stem cells can take up the bacteria contained in MV130 and modify their functionality towards pro and anti-inflammatory responses in a controlled sequential way.
More info

October 2020

Peach tree pollen can be the cause of allergic rhinitis and asthma in exposed workers according to a paper published in Occupational and Environmental Medicine. Pru p 9 is identified as one of the relevant allergens and peach tree pollen is described as a cause of occupational allergy not previously described. The study opens the possibility of this type of allergy in workers with high exposure to entomophilous pollinating flowers, whose pollen has not been considered clinically relevant to date.
More info

August 2020

A systematic review on the role of UROMUNE (MV140) in the prevention of rUTI (recurrent urinary tract infections) has been published. The study, led by Dr. J. Curtis Nickel (Queen's University, Canada), has taken into account published clinical data conducted with this vaccine. UROMUNE (MV140) is a sublingual vaccine developed and manufactured by INMUNOTEK that includes the main bacteria that cause recurrent urinary infections.
More info

July 2020

MV130 (Bactek) previene infecciones respiratorias recurrentes en enfermos con inmunodeficiencia variable común (CVID) según un estudio piloto publicado en Biomedicines. El estudio es una prueba de concepto para valorar MV130 como vacuna TIbV de inmunidad entrenada (trained immunity-based vaccine) en pacientes CVID con infecciones respiratorias recurrentes a pesar del tratamiento profiláctico con inmunoglobulinas de reemplazo y antibióticos.
More info

March 2020

The research study on the effect of aluminum in the new allergoid-mannan conjugates carried out at the Complutense University of Madrid and INMUNOTEK published in Allergy, has been selected to be included in the opening issue of the Virtual Issue collection, aimed to promote the dissemination of outstanding studies.
More info

December 2019

Financial Times features INMUNOTEK as an example of a Spanish company with strong growth along the years even in unfavorable situations. According to the economic newspaper, the strength of these companies is based on their commitment to innovation and competitiveness. This allows to focus its productive activity towards foreign markets, have a sustained growth and create employment.
More info

November 2019

The Spanish Ministry of Science, Innovation and Universities has awarded INMUNOTEK the National Innovation Award 2019. This price, the highest award granted in Spain to distinguish companies that make innovation their main business growth strategy, is endowed with 30,000 euros and has been granted to INMUNOTEK in the category of "Small and Medium-Sized Enterprise".
More info